Skip to main content

Table 1 Correlation between circFBXL5 expression and the clinicopathological features of breast cancer patients

From: CircFBXL5 promotes the 5-FU resistance of breast cancer via modulating miR-216b/HMGA2 axis

Clinicopathologic features

Relative circFBXL5 level

P value

High (%)

Low (%)

Age (years)

  

0.2493

 ≥ 55

15 (55.6)

12 (44.4)

 

 < 55

9 (75.0)

3 (25.0)

 

Tumor size (cm)

  

0.0181*

 ≥ 3

10 (90.9)

1 (9.1)

 

 < 3

14 (50.0)

14 (50.0)

 

TNM stage

  

0.0052*

 I + II

12 (46.2)

14 (53.8)

 

 III

12 (92.3)

1 (7.7)

 

ER status

0.8759

 Negative

9 (60.0)

6 (40.0)

 

 Positive

15 (62.5)

9 (37.5)

 

PR status

0.6729

 Negative

8 (57.1)

6 (42.9)

 

 Positive

16 (64.0)

9 (36.0)

 

HER2 status

0.2677

 Negative

17 (680.0)

8 (32.0)

 

 Positive

7 (50.0)

7 (50.0)

 
  1. *P < 0.05